Azitra, Inc. Stock-Based Compensation
Azitra, Inc. (AZTR) reported Stock-Based Compensation of $17.55 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Azitra, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $11.40K, a 28.86% decline year-over-year.
- Azitra, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.15K, a 79.77% decline year-over-year.
- Azitra, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $12.15K, a 63.39% decline year-over-year.
- Azitra, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.17K, a 97.10% decline year-over-year.
- Azitra, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $62.74K, a 74.40% decline from fiscal 2024.
- Azitra, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $245.05K, a 61.75% increase from fiscal 2023.
- Azitra, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $151.50K, a 17.87% decline from fiscal 2022.
- Azitra, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $184.47K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $11.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $17.55K 10-Q · filed 2026-08-12 | $29.70K derived: sum of 3 quarters · filed 2026-08-12 | $33.87K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $6.15K 10-Q · filed 2026-05-13 | $18.30K derived: sum of 2 quarters · filed 2026-05-13 | $22.46K derived: sum of 3 quarters · filed 2026-05-13 | $38.49K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $12.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $16.31K derived: sum of 2 quarters · filed 2026-02-27 | $32.34K derived: sum of 3 quarters · filed 2026-08-12 | $62.74K 10-K · filed 2026-02-27 | |
| 2025-09-30 | $4.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $20.20K derived: sum of 2 quarters · filed 2026-08-12 | $50.60K 10-Q · filed 2025-11-12 | $83.78K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $16.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $46.43K 10-Q · filed 2026-08-12 | $79.61K derived: sum of 3 quarters · filed 2026-08-12 | $223.15K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $30.40K 10-Q · filed 2026-05-13 | $63.58K derived: sum of 2 quarters · filed 2026-05-13 | $207.11K derived: sum of 3 quarters · filed 2026-05-13 | $241.28K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $33.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $176.71K derived: sum of 2 quarters · filed 2026-02-27 | $210.88K derived: sum of 3 quarters · filed 2026-02-27 | $245.05K 10-K · filed 2026-02-27 | |
| 2024-09-30 | $143.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $177.70K derived: sum of 2 quarters · filed 2025-11-12 | $211.88K 10-Q · filed 2025-11-12 | $246.72K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $34.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $68.34K 10-Q · filed 2025-08-11 | $103.19K derived: sum of 3 quarters · filed 2025-08-11 | $142.26K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $34.17K 10-Q · filed 2025-05-13 | $69.02K derived: sum of 2 quarters · filed 2025-05-13 | $108.09K derived: sum of 3 quarters · filed 2025-05-13 | $146.88K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $34.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $73.92K derived: sum of 2 quarters · filed 2025-02-24 | $112.71K derived: sum of 3 quarters · filed 2025-02-24 | $151.50K 10-K · filed 2025-02-24 | |
| 2023-09-30 | $39.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $77.87K derived: sum of 2 quarters · filed 2024-11-12 | $116.66K 10-Q · filed 2024-11-12 | $145.99K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $38.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $77.59K 10-Q · filed 2024-08-12 | $77.59K 10-Q · filed 2023-08-14 | $106.91K derived: sum of 3 quarters · filed 2024-08-12 | $151.24K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $38.79K 10-Q · filed 2024-05-09 | $68.12K derived: sum of 2 quarters · filed 2024-05-09 | $112.45K derived: sum of 3 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $29.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $73.66K derived: sum of 2 quarters · filed 2024-03-15 | $184.47K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $44.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $155.14K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $110.81K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |